Please type a plus sign (+) inside this box ?

[+]

PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute fo	or form 1	449A/PT	0					Comp	olete If	Known	
INF	ORM	ATIO	N DISCLO	SHR	E ST	TATEMENT		_			
1141.	OKW		AN APPLI								
	a		many sheets		2045	r r					ŀ
	(,	250 US	many sheet.	, us m		4.37	Application Nu	ımber	09/51	8.931	-
				- 1	0	man El	Filing Date			13, 2000	
				- 1		uct 5 2 stans 2	First Named II	nventor	Gentz		-
				- 1		<u> </u>	Group Art Unit		1632	- 1624	
					1	AL CHIEF	Examiner Name	e	Unass		
Sheet	•	1		of		WENT & VO	Attorney Docke	et Number	PF45	4P1	
						U.Ş.	PATENT DOC	UMENTS			
		<u> </u>	U.S. Patent Doc					Date of Public		Pages, Columns, Lines, Wh	
Examiner Initials	Cite No. 1		Number	Kind C		Name of Patentee of Cited Door		of Cited Docu MM-DD-Y		Relevant Passages or Relev Figures Appear	ant
FAR	AA	<del>                                     </del>	5,741,667	(II KIIC	J W11)	Goeddel et al.	anen	04-21-9		Tigures Appear	$\neg$
GA	AB	<del> </del>	5,885,800			Emery et al.		03-23-9	_	· · · · · · · · · · · · · · · · · · ·	
-711T	<u> </u>	<del> </del>	2,002,000			Linery of ur.		05-25-7			$\dashv$
							·				
						FORFI	GN PATENT D	OCUMENTS			$\overline{}$
	<u> </u>	F	oreign Patent Do			I		Date of Public		Pages, Columns, Lines,	П
Examiner Initials	Cite No. 1	Office <sup>3</sup>	Number4	Kind C		Name of Patentee of Cited Doc		of Cited Docu MM-DD-Y		Where Relevant Passages or Relevant Figures	
Tittiais	140.	Offices	14dilloci4	(11 KII)	owii)	Ched Doc	ument	IVIIVI-DD-1		Appear	Te
ENT	AC		WO95/330	051		Genentech Inc., e		12-07-9	5		
D)	AD		WO96/340	)95		Human Genome	Sciences,	10-31-9	6		
4						Inc. et al.					
€4	ΑE		WO98/300	594		Human Genome S	Sciences,	07-16-9	8		
41						Inc., et al.					
FλΔ	AF		EP 0 861	350		SmithKline Beec	ham	09-02-9	8		
ATT						Corporation					
		11	ОТ	HER R	REFE	RENCES - NON PA	TENT LITERA	TURE DOCUM	IENTS		•
Examir	ner	Cite	Include	name o	f the	author (in CAPITAL I	LETTERS), title	of the article (wh	nen app	ropriate), title of the item	-
Initial	ls	No. 1	(book, m	agazin	e, jou	rnal, serial, symposius	n, catalog, etc.), od/or country whe	date, page(s), vo	lume-is	sue number(s), publisher,	Тé
	^	AG	Genbank	Acces	ssior	Number AA025					
<i>G</i> /7	<i>T</i>						`	<u> </u>	1 10	(100=)	
EH	-	AH	KWON e	t al., 7	The J	Iournal of Biologi	cal Chemistry	y, 272:14272 <b>-</b>	14276	(1997)	
Sitt	-	ΑĪ	GenBank	Acce	ssio	n Number W6756	0 (10-16-96)				
GN	<del></del>	AJ	GenBank	GenBank Accession Number M91489 (10-29-92)							
		AK		GIESER et al., <i>Genomics</i> , 13(3):873-876 (7-92)							
<i>A</i> A		A T						)()			
EA		AL				nome Research, 6	•	/o) 			
Et	*	AM				2, 396:699-703 (12					
ফ্র	A- 1	AN					- · · · ·			ternational Application	
4,	•		No. PCT/	<del>US00</del>	7056	180 CM	sidered,	de not	P	ublish	
Examine	r	50	R	2 4	1/		Date Consid	dered o/.	2//0	. 1	
		rlea	~ B.	0/	Y a	<u>~a</u>	<u> </u>	-/-	-1/0		
							, (				

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute f	or form 1449A/PTO			Complete If Known			
INF	ORMATION DISCL IN AN APPI (use as many shee	LICATI	ON PE JOS				
			7.7000	Application Number	09/518,931		
			1 - 7 - 4	Filing Date	March 3, 2000		
			I DEC. SE	First Named Inventor	Gentz et al.		
			The season	Group Art Unit	1632 1646		
			18 TRA	Examiner Name	Paras II.P. Eilen B.071ara		
Sheet	1	of	2	Attorney Docket Number	PF454P1		

			 U.S. PATENT DOC	UMENTS	
Examiner Initials	Cite No. 1	U.S. Patent Document Kind C Number (if kno	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
an	AO	5,632,994	REED ET AL.	05-27-97	
ENT	AP	5,874,546	NAGATA ET AL.	02-23-99	
EA	AQ	5,652,210	BARR ET AL.	07-29-97	
CM	AR	5,663,070	BARR ET AL.	09-02-97	
an	AS	5,620,889	LYNCH ET AL.	04-15-97	
CA.	AT	5,830,469	LYNCH ET AL.	11-03-98	

			FOREIGN PATENT DO	OCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Kind C Office <sup>3</sup> Number4 (if kno	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
E2#	AU	WO00/46247	MERCK & CO., INC.	08-10-00		
CM	AV	WO00/34782	ELI LILLY AND COMPANY	06-15-00		
ETA	AW	WO99/14330	GENENTECH, INC.	03-25-99		
EA	AX	WO00/53755	GENENTECH, INC.	09-14-00		
ÉM	AY	WO00/53223	HUMAN GENOME	09-14-00		
411			 SCIENCES, INC.			
EGA.	AZ	WO00/32221	 GENENTECH, INC.	06-08-00		
2/1	BA	WO00/53758	GENENTECH, INC.	09-14-00		
CA	BB	WO00/37094	ELI LILLY AND COMPANY	06-29-00		
E14	BC	WO00/58465	ELI LILLY AND COMPANY	10-05-00		
cint	BD	WO0058466	ELI LILLY AND COMPANY	10-05-00		
giA.	BE	WO00/01817	SCHERING CORPORATION	01-13-00		
اميحا	BF	WO99/07738	REGENERON	02-18-99		
GM			PHAMACEUTICALS, INC.			
211	BG	WO99/04001	ZYMOGENETICS, INC.	01-28-99		<u> </u>
974	BH	WO99/26977	 BIOGEN, INC.	11-24-98		
an	BI	WO99/46376	BASF AKTIENGESELLSCHAFT	09-16-99	Abstrate	
and.	BJ	WO98/56892	HUMAN GENOME SCIENCES, INC.	12-17-98		
EXA	BK	WO99/33980	CHIRON CORPORATION	07-08-99		
EN.	BL	WO99/11791	UNIVERSITY OF WASHINGTON	03-11-99		
<u> </u>	BM	WO99/31128	INCYTE	06-24-99		<del>                                     </del>
EM			PHARMACEUTICALS, INC.			
DA.	BN	WO00/60079	CHIRON CORPORATION	10-12-00		
CAA	ВО	WO99/50413	ELI LILLY AND COMPANY	10-07-99		

Ela B.0//m 2/23/01

File Ggs

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

## RECEIVED

Substitute for form			SHR	E STATEMENT		Complete If Known DEC 1 5 2008				
nuron				IONOE						
	11 7 A A D L N	nany sheets	20.1							
'	(use as n	naily sheets	as 11		Application Number 09/518,931					
			i	一 。 如 對	• •					
				1 m	Filing Date First Named Inventor	March 3, 2000 Gentz et al.				
				A OFF	Group Art Unit Examiner Name	19/6				
THIT & TRAIL				PATA TRIV		Peras Jr. D. Eilen B. Ollara				
Sheet	2	l_	of	- 2	Attorney Docket Number	<u>. 1</u>				
		OT	HER	REFERENCES - NON PA	TENT LITERATURE DO	CUMENTS				
Examiner Initials	Cite No. <sup>1</sup>			e, journal, serial, symposiur		e (when appropriate), title of the item s), volume-issue number(s), publisher, d.				
_	BP	KIKUNO	et al	., "Prediction of the Co	oding Sequences of Un	identified Human Genes, XIV, the				
ENA		Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins in								
911				esearch 6:197-205 (199						
EM	BQ	BAI et al., gene ampl	"Ov ificat	erexpression of M68/D tion and its location in	ocR3 in human gastroin a four-gene cluster," Pl	ntestinal tract tumors independent of NAS 97(3):1230-1235 (02-01-00)				
GA .	BR	Suppresse	YU et al., "A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis," The Journal of Biological Chemistry 274(20):13733- 13736 (05-14-99)							
EM	BS	RABINO	RABINOWICH et al., "Lymphocyte Apoptosis Induced by Fas Ligand-expressing Ovarian Carcinoma Cells," J. Clin. Invest. 101(11):2579-2588 (06-98)							
8M	ВТ	WALKER Opinion in	WALKER et al., "Tumor expression of Fas ligand (CD95L) and the consequences," Current Opinion in Immunology 10:564-572 (1998)							
8M	BU	Expression	GRATAS, et al., "Up-Regulation of Fas (APO-1/CD95) Ligand and Down-Regulation of Fas Expression in Human Esophageal Cancer," Cancer Research 58:2057-2062 (05-15-98)							
9VA	BV	BUZYN e Tumor Im	t al., mune	"Membrane-Bound Fa Escape in Leukemia l	s (Apo-1/CD95) Ligan Patients," Blood 94(9):	d on Leukemic Cells: A Mechanism of 3135-3140 (11-01-99)				
Examiner	<del></del>	Le B.			Date Considered	2/23/1				

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.